K.J. Harrison & Partners Inc lessened its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 43.5% during the 1st quarter, Holdings Channel reports. The firm owned 13,000 shares of the company’s stock after selling 10,000 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Zoetis were worth $1,537,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the business. Global Wealth Strategies & Associates acquired a new position in Zoetis in the fourth quarter worth $25,000. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the fourth quarter valued at approximately $30,000. Root Financial Partners LLC boosted its position in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis in the 3rd quarter valued at $31,000. 92.80% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Zoetis
In other news, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 11,650 shares of company stock worth $886,384 in the last quarter. Company insiders own 0.22% of the company’s stock.
Zoetis Trading Down 0.1%
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.
Zoetis Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.8%. Zoetis’s payout ratio is 35.16%.
Trending Headlines about Zoetis
Here are the key news stories impacting Zoetis this week:
- Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
- Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
- Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
- Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…
Analysts Set New Price Targets
A number of research firms recently issued reports on ZTS. Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Stifel Nicolaus decreased their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. dropped their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $126.92.
View Our Latest Stock Report on ZTS
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
